UPC after one month: Life sciences cases


Joanne Welch and Darren Smyth

UPC after one month: Life sciences cases

LCV / Shutterstock.com

Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.

The Unified Patent Court’s (UPC) doors have been open since June 1. One month on, there is an opportunity to consider which parties have decided to dip their toes into the waters of the new court for their life sciences matters.

First up we have Sanofi/Regeneron and Amgen. These parties have previously locked horns in Germany in relation to Amgen’s EP2215124 and Regeneron’s Praluent cholesterol lowering medication.

Now at the UPC, Amgen has, on the first day, filed an infringement action in the Munich local division in relation to its EP3666797. This was only granted on May 17, 2023, titled “Antigen Binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)”, with the invention said to be useful for treating or preventing hypercholesterolemia.

patents, unified patent court, UPC, EPO, infringement, revocation, munich, Sanofi, Regeneron, Amgen, 10X Genomics, Vizgen, NanoString Technologies, astella